EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity

Dean Nehama, Alex S Woodell, Spencer M Maingi, Shawn D Hingtgen, Gianpietro Dotti

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noad092 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Dean Nehama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Montefiore Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, American Association for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a highly aggressive tumor with a devastating impact on quality-of-life and abysmal survivorship. Patients have very limited effective treatment options. The successes of targeted small molecule drugs and immune checkpoint inhibitors seen in various solid tumors have not translated to GBM, despite significant advances in our understanding of its molecular, immune, and microenvironment landscapes. These discoveries, however, have unveiled GBM’s incredible heterogeneity and its role in treatment failure and survival. Novel cellular therapy technologies are finding successes in oncology and harbor characteristics that make them uniquely suited to overcome challenges posed by GBM, such as increased resistance to tumor heterogeneity, modularity, localized delivery, and safety. Considering these advantages, we compiled this review article on cellular therapies for GBM, focusing on cellular immunotherapies and stem cell-based therapies, to evaluate their utility. We categorize them based on their specificity, review their preclinical and clinical data, and extract valuable insights to help guide future cellular therapy development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansTreatment OutcomeImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

cell therapyglioblastomaimmunotherapystem cell therapytumor heterogeneity

Autor:innen und Institutionen

  • Department of Internal Medicine, Montefiore Medical Center, New York, New York, USA.
  • Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • American Association for Cancer Research

Zitieren

APA

Nehama, D., Woodell, A. S., Maingi, S. M., Hingtgen, S. D., & Dotti, G. (2023). Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad092

Vancouver

Nehama D, Woodell AS, Maingi SM, Hingtgen SD, Dotti G. Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad092

BibTeX
@article{Nehama2023,
  author = {Nehama, Dean and Woodell, Alex S and Maingi, Spencer M and Hingtgen, Shawn D and Dotti, Gianpietro},
  title = {Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noad092}
}
Kostenlos starten →